Healio Rheuminations
Rheumatology is an incredibly fast-moving and exciting field of medicine that can be difficult to keep up with. This Healio podcast provides busy clinicians with quick updates in the field of autoimmunity, with emphasis on new medications, treatment guidelines and explorations into the pathophysiology of diseases. The show will also feature historical perspectives in the field of rheumatology, as well as fascinating case presentations of medical mysteries complete with discussions from experts in the field.
info_outline
The Astounding Account of the IL-17 and Spondylarthritis
07/28/2025
The Astounding Account of the IL-17 and Spondylarthritis
In this episode, we focus on the history of researchers discovering the clinical applicability of the IL 23/17 axis, with a particular emphasis on psoriasis, psoriatic arthritis and axial SpA · Intro 0:01 · In this episode 0:12 · Leonard Calabrese, DO, is listening! 0:54 · Recap of last episode 3:09 · Putting the pieces together 5:12 · Quick overview of this science heavy episode 6:11 · What is psoriasis? 7:26 · Immunosuppressants for psoriasis/ Throwing meds at people and seeing what happens 10:10 · In the modern world of 1986 – olive oil placebo trial 11:36 · A quick aside into fungi 12:35 · What kind of T-cells are involved here? 16:41 · The TH-1 hypothesis 18:20 · IL-23 and IL-17 are doing something 19:34 · Going back to the drawing board in 2004 20:00 · p40 + p19 = IL-23 21:00 · IL-23 via minicircle DNA in mice 23:05 · Brand new and shiny TH-17 25:23 · The family of IL-17 26:36 · What do we know about IL-17 and psoriasis? 27:10 · IL-17A vs IL-17F in mouse studies 27:35 · Finding the difference between IL-17A and IL-17F in humans 28:23 · What exactly is IL-17 doing? 29:30 · The articular manifestations of psoriatic arthritis 30:57 · Spondylarthritis and the IL 23/17 axis 33:56 · T-cells we haven’t talked about 35:40 · Summary of this episode 39:08 · Thanks for listening 41:34 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Disclosures: Brown reports no relevant financial disclosures.
/episode/index/show/rheuminations/id/37576790
info_outline
The Tumultuous Tale of Th17-and the IL23/IL17 immune axis
06/30/2025
The Tumultuous Tale of Th17-and the IL23/IL17 immune axis
In this episode, we dive into a two-part story of intrigue starting from a paradigm shift in understanding of T cell biology because of a mouse model of post-measles encephalopathy, to the eventual recognition of the IL-23/17 immune axis. • Intro 0:01 • In this episode 0:12 • Interleukin-17 (IL-17) is a relatively recent discovery 1:34 • The beginning of TH-17 2:20 • Looking at autoimmune encephalopathy: A story of measles 03:30 • 1790’s woman with post measles inflammatory process in the brain 10:26 • What is causing post-infection encephalitis? 12:00 • Acute disseminated encephalomyelitis 12:30 • How did we find out the immune system was behind this - The rabies vaccine 13:09 • Similarity between the rabies vaccine and infections like measles 16:04 • T-cell lymphocytes 17:12 • The forgotten thymus 18:00 • What’s the function of T-cells? 19:35 • How do you tell T-cells apart? 21:14 • The Human Leukocyte Differentiation Antigens Party 24:05 • The godfather of T-cells 24:45 • The TH-1 and TH-2 axis 27:30 • Experimental Autoimmune Encephalomyelitis model screwed everything up 29:16 • Interferon gamma 32:32 • What’s missing? IL-23 surprise 33:40 • IL-17 in the 1990’s 36:44 • The world is introduced to TH-17 39:12 • Let’s recap what we learned 40:30 • That is the end! 42:30 • Thanks for listening 42:39 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Disclosures: Brown reports no relevant financial disclosures.
/episode/index/show/rheuminations/id/37220670
info_outline
History of polymyalgia rheumatica: The origin of the pain & link to giant cell arteritis
05/30/2025
History of polymyalgia rheumatica: The origin of the pain & link to giant cell arteritis
In this episode, we dive into the history of polymyalgia rheumatica, how it was discovered and its link to giant cell arteritis. Intro 0:01 In this episode 0:10 What is polymyalgia rheumatica (PMR)? 0:24 The history of PMR 02:12 PMR in the 1950s: A formally recognized disease 04:52 What was probably PMR in the 1880s 06:27 Naming PMR: Senile rheumatic gout 07:26 1957: The witch’s shot and finally landing on polymyalgia rheumatica 08:30 Where is PMR coming from? 14:42 Injecting joins with saline 16:39 A biopsy study in 1964 19:54 Technetium bone scintigraphy in 1971 and bone scan history 23:01 First look at a PMR ultrasound in 1993 27:00 1997: First use of MRI on PMR patients in Italy 27:49 Going back to 1962: PMRs association with giant cell arteritis 30:40 A paper on muscular involvement in giant cell arteritis: 80-year-old ‘robust’ partially blind seaman 32:15 First systematic approach: The link between PMR and giant cell arteritis 35:14 80 cases of PMR 38:13 Swedish autopsy studies 41:07 Introduction of advanced imaging in the 1990s 42:40 Summing up PMR through the decades 43:28 That is the end! 45:25 Thanks for listening 45:50 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Cantini F, et al. J Rheumatol. 2001;28(5):1049-55. Disclosures: Brown reports no relevant financial disclosures.
/episode/index/show/rheuminations/id/36790360
info_outline
Pulmonary hypertension, part 4: The therapeutics, with Dr. Joseph Parambil
04/23/2025
Pulmonary hypertension, part 4: The therapeutics, with Dr. Joseph Parambil
In the final part of this series, Joseph Parambil, MD, walks us through the approach of managing pulmonary hypertension, reviews the pathophysiology and digs into the mechanisms and the differences in the medications. Intro 0:12 In this episode 0:17 Interview with Joseph Parambil, MD 2:53 Reviewing and clarifying pathophysiology prior to initiating therapeutics 4:13 Evaluating patients in terms of their functional status and how does that play a role in initiating therapies 4:25 Vasoreactivity testing 10:21 The categories of medications 14:40 Endothelin receptor antagonists 37:07 TGF pathway 42:13 Scleroderma patient and treatment 50:19 Do patients get a repeat right-heart catheterization? 55:51 What about the TGF-beta? 56:55 Thank you, Dr. Parambil 58:34 Thanks for listening 59:17 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . Disclosures: Brown and Parambil report no relevant financial disclosures. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic’s Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine.
/episode/index/show/rheuminations/id/36277755
info_outline
Pulmonary hypertension, part 3: Early therapies and vascular physiology
03/25/2025
Pulmonary hypertension, part 3: Early therapies and vascular physiology
In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension. Intro 0:12 In this episode 0:18 Recap of part 1 & 2 0:31 What part 3 is about 2:31 WHO conference in 1975: Treating pulmonary hypertension 3:48 5:20 Epoprostenol 6:18 Prostacyclin 10:37 Endothelin antagonists 11:41 Phosphodiesterase type 5 (PDE5) inhibitors 14:08 Interaction of nerves and blood vessels 15:06 The Soups VS the Sparks 17:36 A dreamed experiment 19:06 Acetylcholine 23:23 Enter “the calabar bean” 24:45 Acetylcholine and vasodilation: 1976 26:01 Rabbit aorta 27:45 Nitric oxide 29:38 Why are we using nitric oxide to treat pulmonary hypertension? 31:31 Tachyphylaxis 33:48 TNT factories 35:09 Nitrous oxide and tachyphylaxis 36:52 Pfizer in the 1980s 38:06 Understanding the trigger of pulmonary hypertension 40:53 PDE5 and nitric oxide and pulmonary hypertension 43:07 The end of the ripping yarns 44:20 Coming up in part 4 46:17 Thanks for listening 47:29 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Bernard C. C R Soc Biol. 1851;3:163-164. Warren JV. Trans Am Clin Climatol Assoc. 1988;99:10-6. Disclosures: Brown reports no relevant financial disclosures.
/episode/index/show/rheuminations/id/35854505
info_outline
Pulmonary hypertension and the rheumatologist, part 2: The history
02/26/2025
Pulmonary hypertension and the rheumatologist, part 2: The history
In part 2, we dig into the history of pulmonary hypertension. How did this strange diagnosis first get recognized, what does it have to do with cows with thick necks and urinary catheters in the heart? Intro 0:11 In this episode 0:17 Recap of part 1 0:26 How was pulmonary hypertension discovered? 2:38 1891 3:51 1901 5:07 1935 7:02 Hilar dance 12:58 Cardiac catheterization: 1929 15:03 When did cardiac catheterization become relevant? 20:10 1965: Aminorex 24:40 World Health Organization: 1975 26:37 1980s: toxic oil syndrome of Spain 28:20 Preview of part 3 33:15 Back to cardiac catheterization 34:08 Briskets disease 35:45 1947 37:56 Pulmonary physiology and prostaglandin therapies (in the next episode) 38:41 Schistosomiasis outbreaks in Egypt 1938 40:26 Chronic thromboembolism 45:03 Thanks for listening 48:16 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Egypt. Stanford.edu. Published 2015. https://schisto.stanford.edu/pdf/Egypt.pdf. Disclosures: Brown reports no relevant financial disclosures.
/episode/index/show/rheuminations/id/35436070
info_outline
Pulmonary hypertension and the rheumatologist, part 1: A bit of background
02/12/2025
Pulmonary hypertension and the rheumatologist, part 1: A bit of background
In this series, we dive into what rheumatologists should know about pulmonary hypertension, starting an interview with Joseph Parambil, MD, where we learn about the disease, when to suspect and how to work up! Intro 0:11 In this episode 0:16 Preview of the four-part series 4:46 Interview with Joseph Parambil, MD 6:27 How did you become interested in pulmonary hypertension? 7:02 Brown and Parambil discuss the histology of pulmonary hypertension. 10:13 Brown and Parambil discuss a case of pulmonary hypertension. 12:26 What is pulmonary hypertension and what does that mean for a rheumatologist? Where is pulmonary hypertension happening? 13:25 Describe the different groups of pulmonary hypertension. 19:51 A note about Dr. Chatterjee 20:25 Brown and Parambil discuss the groups of pulmonary hypertension. 23:35 What should we know about evaluating patients with pulmonary hypertensions? 26:51 Brown and Parambil discuss bendopnea and other signs of pulmonary hypertension. 29:58 What about the heart sound? 33:06 What should we look for in patients who we suspect to have pulmonary hypertension? 36:52 What should we look for in the tricuspid jet? 38:18 Brown and Parambil discuss the use of echocardiograms in pulmonary hypertension. 39:28 Tell us about the threshold of diagnosis. 40:47 What is the difference between the mean pressure and the wedge pressure? 41:41 What about the role of the pulmonary function test? 43:55 Summary 46:41 Do you think the pulmonary hypertension in scleroderma and lupus are different entities? 48:37 Brown and Parambil discuss the connection of autoimmune disease and pulmonary hypertension. 50:49 Coming up in episode 91 51:50 Thanks for listening 52:25 Disclosures: Brown and Parambil report no relevant financial disclosures. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic’s Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter .
/episode/index/show/rheuminations/id/35227620
info_outline
COVID's role in autoimmunity and where we are in the world of long COVID
01/22/2025
COVID's role in autoimmunity and where we are in the world of long COVID
On this episode, hear the 2024 updates on COVID-19, long COVID and the latest developments in research in rheumatology. Hosted by Dr. Leonard Calabrese. Intro 0:12 In this episode 0:21 Coming up on Healio Rheuminations 0:56 2:19 Questions 3:12 Long COVID 4:46 Calabrese’s bias 10:15 The evidence 13:08 Auto antibodies 14:54 Why does the body develop auto antibodies? 17:47 COVID-19 and epidemiologic association 22:25 New clinical entity 26:40 Therapeutic implications 31:00 In conclusion 32:00 Thanks for listening 33:18 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter .
/episode/index/show/rheuminations/id/34955375
info_outline
The Story of the Flu Vaccine (Re-Release)
10/24/2024
The Story of the Flu Vaccine (Re-Release)
It's that time of year again, everyone rolling up their sleeves to get a flu shot. This throwback episode dives into the history of the struggles pinning down the causative agent of flu and the journey to the vaccine! Intro 0:40 In this episode 1:11 The history of the flu: 1892 1:41 What do we know about viruses? 6:29 Rabies and dead virus 11:17 14:43 1918 16:44 Vaccines and trials 19:13 Pig influenza 23:12 Influenza: a filterable agent we can’t see 27:01 The trials of 1942 33:02 PS: 1918 influenza 38:57 Thanks for listening 47:42 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: . Rosenau MJ. Experiments Upon Volunteers to Determine the Cause and Mode of Spread of Influenza, Boston, November and December, 1918. Accessed December 6, 2023. Tobin J. The first flu shot. . Accessed December 6, 2023.
/episode/index/show/rheuminations/id/33596927
info_outline
NSAIDs, Part 3: The rise, fall and rise again of COX-2 inhibition
08/29/2024
NSAIDs, Part 3: The rise, fall and rise again of COX-2 inhibition
In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology? Intro 0:11 Recap of part 1 & 2 0:28 In this episode 1:44 Cyclooxygenase 2 (COX-2) and the rat experiment 3:12 What do we know about the prostaglandins? And what about COX-2 7:54 What does prostacyclin do? 10:33 The first COX-2 inhibitor: VIOXX 10:56 What is COX-2 doing?: Pfizer and Merck 12:15 Two more NSAID studies: colon cancer, Alzheimer’s disease and COX-2 inhibitors 18:41 VIOXX: Why is myocardial infarction risk occurring? 22:34 Animal models and the Goldilocks theory of thromboxane and prostacyclin 23:49 PRECISION trial 30:25 37:14 Thanks for listening 37:32 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Disclosures: Brown reports no relevant financial disclosures.
/episode/index/show/rheuminations/id/32791147
info_outline
NSAIDs, Part 2: The Dawn of the Anti-Inflammatories
06/26/2024
NSAIDs, Part 2: The Dawn of the Anti-Inflammatories
In this episode, we dive into the story of aspirin and the development of ibuprofen, ending with the experiments that showed the mechanism of how aspirin actually works. Intro 0:12 Review of part 1 0:28 In this episode 1:04 Blocking prostaglandins and willow leaves 2:26 Edward Stone 3:45 Johann Andreas Buchner 4:16 The chemical structure of salicylic acid and creating the synthetic compound 4:44 Dr. TJ MacLagan: The first trial in 1876 and treating acute rheumatism 5:16 Felix Hoffmann: manipulating salicylic acid and aspirin 8:47 How widespread was the use of aspirin for rheumatoid arthritis? 12:04 1938: problems with aspirin and endoscopies 14:58 1950s: long-term use of aspirin and chronic renal impairment 17:12 Dr. Lawrence Craven: the use of aspirin to treat myocardial infarction 18:13 Overview of what we’ve learned so far 20:48 Stewart Adams: the development of ibuprofen 21:40 A paper lost to time 23:29 How do you test if a drug is anti-inflammatory? 25:25 How do you make better aspirin? 26:55 1960: a trial comparing ibuprofen, baby aspirin and prednisone in patients with rheumatoid arthritis 30:03 Aspirin, ibuprofen and other NSAIDs 32:49 Nobel Prize winner Dr. John Vane 33:40 Dr. Vane: what triggered prostaglandin production? 35:42 Another guinea pig experiment 37:37 Nobel Prize winner Dr. Bengt Samuelsson 39:00 Interesting tidbits: early studies looking at the side effects of NSAIDs 40:01 1968: gastric ulcer formation and prostaglandins in rats 40:25 1973: renal blood flow and prostaglandins in dogs 41:53 1974: aspirin vs ibuprofen vs indomethacin for the heart 44:03 Aspirin vs ibuprofen vs indomethacin 44:20 On the next episode 46:09 Thanks for listening 46:37 We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: . Harris SC, Fosdick LS. Theoretical considerations of the mechanisms of antipyretic analgesia. NWU Bull. 1952;53: 6–9. Disclosures: Brown reports no relevant financial disclosures.
/episode/index/show/rheuminations/id/31896492
info_outline
The Discovery of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Part 1
05/16/2024
The Discovery of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Part 1
Humans have had an insatiable appetite for inhibiting production of prostaglandins for centuries! This series delves into the history of aspirin and NSAIDs, looking at the understanding of the prostaglandin pathway. · Intro 0:12 · In this episode 0:23 · What are NSAIDs? 0:53 · Prostaglandins 5:50 · What are prostaglandins? 7:19 · Where do prostaglandins come from? 8:45 · So, what do we do with prostaglandins? 13:15 · How did they figure out prostaglandins? 13:55 · Naming the prostaglandin 21:25 · Phospholipids 24:46 · Arachidonic acid 25:28 · Arachidonic acid into prostaglandins: how do you prove it? 26:32 · How does arachidonic acid turn into prostaglandins? 27:27 · Cyclo-oxygenase 28:36 · mRNA and COX-2 32:50 · On the next episode 35:55 · Summary 36:38 · Thanks for listening 37:49 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: .
/episode/index/show/rheuminations/id/31334822
info_outline
Urticarial Vasculitis, Part 2: Walking the Balance Beam of Allergy and Rheumatology
04/18/2024
Urticarial Vasculitis, Part 2: Walking the Balance Beam of Allergy and Rheumatology
This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin. · Intro 0:11 · In this episode 0:22 · Review of episode 83 1:23 · Listen to previous episode, 4:09 · Anti-C1q antibodies 6:26 · Lupus, anti-C1q and lupus nephritis 9:33 · What happens when you inject anti-C1q in a mouse? 12:56 · The allergy component: anti-C1q, urticaria and angioedema 17:36 · Bradykinin-mediated angioedema and C1q deficiency 24:20 · What is the kinin kallikrein system? 26:21 · French researchers in 1909: human urine injected in dogs 27:30 · How is this relevant to urticarial vasculitis? 31:08 · SERPING1 gene mutation 31:23 · Summary 32:06 · COPD association with urticarial vasculitis 33:51 · Coming up in episode 85 35:28 · Thanks for listening 35:45 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/30882783
info_outline
Urticarial Vasculitis: Attack of the Nettles, Part 1
02/28/2024
Urticarial Vasculitis: Attack of the Nettles, Part 1
Is it an allergy or an autoimmune vasculitis, or a little of both? Find out the story of urticarial vasculitis, how this disease was recognized and eventually sorted out from other types of urticaria. · Intro 0:12 · In this episode 0:21 · Case study 1:22 · Chronic spontaneous urticaria, hives and nettles 7:57 · Dermatographism and witchcraft? 10:15 · Causes of urticaria 11:17 · Theory of inflammation and histamines 11:40 · Urticaria and treatments with histamines 12:09 · Types of urticaria 13:02 · Mayo Clinic study 13:39 · 16:10 · Connection between types of urticaria and leukocytoclastic vasculitis 20:02 · More case studies 20:38 · What do we know about treatments? 22:23 · In conclusion 24:15 · Coming up in part two 25:08 · Thanks for listening 25:47 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: McDuffie FC, et al. Mayo Clin Proc. 1973;48(5):340-8.
/episode/index/show/rheuminations/id/30150563
info_outline
COVID-19, long COVID and the rheumatologist with Leonard Calabrese, DO
01/04/2024
COVID-19, long COVID and the rheumatologist with Leonard Calabrese, DO
What should rheumatologists know about what we've learned about COVID-19 and long COVID in 2023? Hosted by Dr. Leonard Calabrese. · Intro 0:11 · In this episode 0:21 · 2023: current status and controversies 0:35 · What is going on with COVID-19? 01:53 · What do we know about vaccine responses? What should we be telling our patients about vaccines in our immunocompromised population? 2:58 · 3:08 · What about patients within the rheumatic and autoimmune disease space? 4:15 · Who is immunocompromised and why does it matter? 5:11 · What is the immunosuppression we are giving them? 6:39 · What to tell patients about getting vaccinated 8:56 · Long COVID 10:09 · What is long COVID? 10:26 · 14:19 · In the clinical arena, what should rheumatologists be thinking about? 16:38 · What about pathogenesis? What do we know about the controversies in this area? 18:58 · Autoimmunity: COVID-19 and autoimmune response 20:45 · What about therapies? 22:22 · 24:40 · A question for the rheumatology community: do patients with immune mediated diseases get more long COVID than the control population? 25:40 · In conclusion 27:37 · Thanks for listening 28:38 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB.. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter .
/episode/index/show/rheuminations/id/29342478
info_outline
The Story of the Flu Vaccine
12/07/2023
The Story of the Flu Vaccine
It's that time of year again, everyone rolling up their sleeves to get a flu shot. This episode dives into the history of the struggles pinning down the causative agent of flu and the journey to the vaccine! · Intro 0:12 · In this episode 0:17 · The history of the flu: 1892 3:10 · Rabies and dead virus 10:52 · 14:31 · Vaccines and trials 19:13 · Pig influenza 23:21 · Influenza: a filterable agent we can’t see 27:10 · The trials of 1942 33:18 · PS: 1918 influenza 39:13 · Finding the 1918 influenza vaccine 39:54 · Thanks for listening 47:54 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Rosenau MJ. Experiments Upon Volunteers to Determine the Cause and Mode of Spread of Influenza, Boston, November and December, 1918. . Accessed December 6, 2023. Tobin J. The first flu shot. . Accessed December 6, 2023.
/episode/index/show/rheuminations/id/28977693
info_outline
It's in the Air: Silica exposure and the risk of autoimmunity, Part 4
11/15/2023
It's in the Air: Silica exposure and the risk of autoimmunity, Part 4
What is silica? How does it impact your risk of developing autoimmunity if you inhale it, inject it or even snort it up your nose? Listen and find out! · Intro 0:12 · In the previous episodes 0:28 · The Ajax incident of 1979 1:15 · Silica and its association with autoimmune disease 4:11 · The history of silica and the health risks 5:21 · Rheumatoid scleroderma, etc. 8:14 · Cardiff pneumoconiosis medical panel 9:49 · Databases 12:51 · Silica exposure and the development of serologies 15:02 · What would happen if you injected silica into the veins? 16:51 · Anca vasculitis 18:33 · Thanks for listening 23:23 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/28657483
info_outline
Autoimmunity, Part 3: The Lupus Gradient
10/30/2023
Autoimmunity, Part 3: The Lupus Gradient
In this episode, we dig through the data of lupus in Africa and speak with experts on the Lupus Gradient, the impact of malaria and what we can learn from it all. · Intro 0:12 · In the previous episode 0:30 · Lupus Gradient 2:01 · Back to Dr. Brian Greenwood 3:48 · Polyarthritis 4:04 · Rates of autoimmune diseases 6:00 · Malaria and mouse models 7:33 · Back to lupus 8:48 · First case of lupus 15:14 · Prevalence of lupus 17:15 · Papers on lupus 21:23 · Dr. Mickael Essouma 23:38 · Dr. Essouma, how did you conduct this study? 24:01 · Did you ever believe there was a gradient? 26:09 · Dr. Sandro Vento 30:56 · Dr. Vento, do you believe there was a lupus gradient? 31:51 · What are the connections to infectious disease? 38:51 · That’s a wrap! 43:04 · Coming up in part 4 44:55 · Thanks for listening 45:05 Disclosures: Brown reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Essouma and Vento at the time of posting. Mickael Essouma, MD, is physician from Cameroon specialized in internal medicine at the University of Yaounde I in Cameroon, with a complimentary certificate on rheumatology from the EULAR online course and a certificate on lupus from the European Lupus Society (SLEuro). He is an advocate of lupus and other autoimmune diseases in Africans. Sandro Vento, MD, is the dean of faculty of medicine at the University of Puthisastra, Phnom Penh, Cambodia and a consultant and collaborating specialist at Mayo Clinic Center for Tuberculosis, WHO Collaborating Center. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/28462250
info_outline
The Geography of Autoimmunity, Part 2
08/17/2023
The Geography of Autoimmunity, Part 2
This episode delves into what we can learn about the impact of the environment on autoimmunity, digging into how rates of autoimmunity can vary drastically in different parts of the world. · Intro 0:12 · In this episode 0:16 · Dr. Brian Greenwood 0:22 · The geography of autoimmunity 7:01 · Type 1 diabetes 10:31 · Finland and type 1 diabetes 13:57 · Socioeconomics 17:59 · Genetics and autoimmune diseases 24:19 · Migration studies 24:53 · Denmark and multiple sclerosis 30:06 · Coming up in part 3 36:02 · Thanks for listening 38:16 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/27781626
info_outline
The Environment and Autoimmunity, Part 1
07/12/2023
The Environment and Autoimmunity, Part 1
This episode delves into the history of the hygiene hypothesis. What do we know about different exposures changing risk for asthma and allergies, and do these exposures have the same protection for autoimmunity? · Intro 0:12 · In this episode 0:18 · Hygiene hypothesis 0:33 · Allergic rhinitis (or Hay fever) 2:32 · Pollen and the allergy skin test 8:58 · Exposure and cleanliness 10:22 · Allergic rhinitis and Cree Native Americans 11:51 · Appendicitis 13:10 · Family size and asthma 14:36 · Rural versus urban populations 17:41 · Dust 18:31 · Children, day care and infections 22:43 · The “old friends” theory 28:29 · Farming and allergies 30:07 · The Amish and the Hutterites 33:02 · Mice, dust and asthma 34:47 · Thanks for listening 37:40 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/27443169
info_outline
An Afternoon with the Glaucomfleckens: On hypermobility and physician burnout
06/28/2023
An Afternoon with the Glaucomfleckens: On hypermobility and physician burnout
On this special episode of Rheuminations, I interview comedian and ophthalmologist William Flanary, MD, and Kristin Flanary, also known as the Glaucomfleckens, on hypermobility and physician burnout. Kristen Flanary highlights what it's like to live with hypermobility, and Dr. William Flanary discusses his thoughts on physician burnout and using their podcast, Knock Knock, Hi, as comedy relief. · Intro 0:11 · In this episode 0:45 · Interview with Dr. William and Kristin Flanary, also known as Doctor and Lady Glaucomflecken 2:49 · Rheumatology and ophthalmology overlap 3:11 · Can you tell me a few things about yourselves? 7:48 · Kristin Flanary, MA: when did you notice your hypermobility and when did you start having complications from it? 12:19 · Do you ever fully dislocate or do you kind of feel like you’re about to? 19:53 · Chest compressions and William Flanary 25:23 · Have you done any bracing? 26:24 · Dr. Linda Bluestein, , on the Glaucomfleckens podcast 30:24 · William Flanary, MD: can you talk about your experience with physician burnout? And are you optimistic about AI solving the physician burnout problem? 31:16 · , 37:01 · Can you tell us more about your podcast, ? 41:06 · Thank you 44:59 Disclosures: Brown and the Flanarys report no relevant financial disclosures. William E. Flanary, MD, is an ophthalmologist and part-time comedian, also known as Dr. Glaucomflecken. You can follow him on Twitter . Kristin Flanary, MA, is a marketing and communications specialist, also known as Lady Glaucomflecken. You can follow her on Twitter . We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter .
/episode/index/show/rheuminations/id/27312462
info_outline
The Black Death and Autoimmunity
04/03/2023
The Black Death and Autoimmunity
Was your psoriasis caused by the Black Death? Learn more than you might have wanted to know about the Black Death and delve into the data on the immunologic/autoimmune ramifications of wiping out nearly half of Europe. · Intro 0:11 · In this episode 1:09 · The Black Death 1:24 · episode 2:07 · How the Black Death happened 4:07 · How many people died from the Black Death? 6:49 · Record keeping 6:53 · The modern immune system, the Black Death and HIV 8:43 · What is CCR5? 8:55 · Current data on autoimmune diseases 10:35 · ERAP2 15:55 · How yersinia pestis kills you 21:04 · The inflammasome 22:03 · episode 22:09 · Mediterranean fever and mouse model 24:49 · Takeaways 30:20 · Summary 30:59 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/26427993
info_outline
Vascular Ehlers Danlos Syndrome for the Rheumatologist, Pt 2: Extra-Cellular Matrix Reloaded
02/28/2023
Vascular Ehlers Danlos Syndrome for the Rheumatologist, Pt 2: Extra-Cellular Matrix Reloaded
In this episode we explore ways in which the extracellular matrix can be manipulated, including the story of doxycycline, TGF-beta in Marfan syndrome and whether beta blockers can reduce vascular events in vascular EDS. · Intro 0:12 · Review of previous episode 0:28 · In this episode 2:26 · The pressure against the vessels 4:06 · The pressure against the wall 8:44 · Matrix metalloproteinases 10:16 · Tadpole study – collagen breakdown 10:35 · Tetracycline antibiotics 14:05 · Rat model – periodontal disease and hydroxyproline 14:24 · Chemically modified tetracyclines 20:14 · Mouse model – tetracycline use 22:00 · Tetracyclines and other autoimmune conditions 23:22 · Marfan syndrome 24:45 · Fibrillin and Marfan syndrome 28:48 · TGF-beta 29:36 · Mouse model – Marfan syndrome and fibrillin 31:14 · ARBs and TGF-beta 33:51 · TGF-beta and vascular EDS 37:25 · Back to the mouse model 38:38 · Protein kinase C 39:56 · Summary 40:26 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/26080956
info_outline
Vascular Ehlers-Danlos Syndrome, Part 1
01/31/2023
Vascular Ehlers-Danlos Syndrome, Part 1
Dive into vascular Ehlers-Danlos syndrome. What is it? How does it present? Get clues to its diagnosis and learn more about collagen than you ever wanted to know. Intro 0:12 In this episode 0:17 Why vascular Ehlers-Danlos syndrome? 0:28 Case study: Dr. Mories 2:20 What can we learn about vascular Ehlers-Danlos syndrome? 05:02 Collagen and elastin 05:57 Collagen: horses and glue 07:07 More about collagen 10:35 Why is it a problem to miss a little bit of collagen? 14:14 The problem in vascular Ehlers-Danlos syndrome 15:06 The history of vascular EDS 15:41 How is vascular Ehlers-Danlos syndrome diagnosed? 16:36 A vascular Ehlers-Danlos syndrome diagnosis 22:33 Mouse models 23:29 Clinical and genetic features of vascular Ehlers-Danlos syndrome 24:39 Question of vasculitis 25:55 The skin: the most common symptom of vascular EDS 28:00 Family history, de novo mutations and pregnancy 29:43 Surgery or vascular intervention 31:39 How do patients do in the long-term? 32:54 Summary 34:00 Preview of part 2 35:42 Thanks 36:25 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References: Barabas AP. J Cardiovasc Surg (Torino). 1972;13(2):160-7. Mories A. Scott Med J. 1960;5:269-72. .
/episode/index/show/rheuminations/id/25788828
info_outline
Making Sense of Sensory Ganglionopathies, Part 2
01/18/2023
Making Sense of Sensory Ganglionopathies, Part 2
In this episode, Dr. Benjamin Claytor walks us through his approach to suspected sensory ganglionopathies. I also cover other neurologic complications of Sjogren’s syndrome and some interesting history on vitamin B6. Intro 0:12 In this episode 0:46 Neurologic complications of Sjogren’s Syndrome 1:55 Intro of Dr. Benjamin Claytor 6:00 The interview 6:49 Case study: process of diagnosis 7:17 Dorsal root ganglion in Sjogren’s 10:46 Facial numbness in sensory ganglionopathies 11:42 Dorsal root ganglion biopsies 13:36 Prognosis of sensory ganglionopathies vs other distal neuropathies 14:03 Sensory loss and weakness 15:51 Sensory ataxia 16:24 Attacks on the dorsal root ganglion 18:25 Loss of fibers in the dorsal root ganglion and regrowth 19:21 Treating cancer and sensory ganglionopathies 20:03 Idiopathic patients and treatments 20:45 Interview wrap-up 21:43 Pearls of wisdom from the interview 22:11 History of sensory ganglionopathies 23:35 Thanks 29:09 Disclosures: Brown and Claytor report no relevant financial disclosures. Benjamin Claytor, MD, is assistant professor of neurology at the Neuromuscular Center at Cleveland Clinic. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter . References:
/episode/index/show/rheuminations/id/25644876
info_outline
Making Sense of Sensory Ganglionopathies and Sjogren’s Syndrome
12/15/2022
Making Sense of Sensory Ganglionopathies and Sjogren’s Syndrome
A sensational (or lack thereof) series on the signs and symptoms of the spellbinding sensory ganglionopathies. Intro :12 Today’s episode :16 Anatomy review 1:32 Large fiber vs. small fiber nerves 4:47 Case presentation 6:11 Neurologic examination of patient 8:31 What is pseudoathetoid posturing? 10:11 What does it mean to be length independent? 14:30 What is sensory ganglionopathy? 16:19 How did the differential evolve throughout history? 18:50 How do things get out of the synovium? 23:19 Why does rheumatology get involved? 26:12 Case series of patients with Sjogren’s syndrome and sensory ganglionopathy 28:20 How do we treat it? 32:48 Summary 34:09 Thank you 36:59 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter References:
/episode/index/show/rheuminations/id/25336446
info_outline
Long COVID: Some facts, unanswered questions and implications for rheumatology – Part 2
10/10/2022
Long COVID: Some facts, unanswered questions and implications for rheumatology – Part 2
In part two, Leonard Calabrese, DO, discusses the symptoms of long COVID and the role that rheumatologists play in diagnosing and treating patients with long COVID. Brought to you by Tremfya. Intro 1:06 Calabrese introduction 1:11 In this episode 1:36 Defining long COVID 1:49 Reviewing symptoms of long COVID 2:51 Long COVID fatigue 3:44 Studies and research on fatiguability 4:38 Phenomena of post-exertional malaise 6:18 Chronic fatigue syndrome 7:25 Neurocognitive dysfunction 7:52 Co-factors of intercurrent mood disorders and neurocognitive dysfunction 9:30 Pandemic-related sequelae 10:30 What about pain? 10:53 Long COVID pain and criteria for fibromyalgia 11:40 Pandemic-related long COVID 13:16 Diagnoses of long COVID 14:46 Immunopathogenesis 15:27 What about infections and autoimmunity? 17:50 What about treatments for long COVID? 19:28 Validation of long COVID 20:52 What do rheumatologists have to do with long COVID? 21:56 Wrap up 21:13 Thanks 24:02 Disclosures: Calabrese reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter
/episode/index/show/rheuminations/id/24618675
info_outline
Long COVID: Some facts, unanswered questions and implications for rheumatology – Part 1
09/30/2022
Long COVID: Some facts, unanswered questions and implications for rheumatology – Part 1
In this episode, Leonard Calabrese, DO, reviews the history and controversies of post-infection sequelae, as well as the facts and epidemiology of long COVID. Intro :12 Calabrese introduction :15 COVID-19 and the history of modern medicine :48 In this episode 1:39 The course of COVID-19 2:05 COVID-19 vaccines and immunity 2:50 Controversy, facts, fascination, long COVID 3:16 The history of post-acute sequelae 3:59 Post-infectious sequelae 10:15 What is long COVID and how do we define it? 11:02 How common is long COVID? 13:50 The epidemiology of long COVID 15:32 What are protective factors? 16:53 Preview of Part 2 17:36 Shoutout to rheumatologists 18:46 Conclusion 19:08 Wrap up of Part 2 preview 20:11 Thanks 21:02 Disclosures: Calabrese reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter
/episode/index/show/rheuminations/id/24543423
info_outline
The Story of the Synovium
08/25/2022
The Story of the Synovium
How is the synovial fluid produced? Who figured it out? It’s a ripping yarn involving corpses, cats, anti-hypertensives, steroids and streptococcus. Brought to you by Tremfya. Intro :11 Today’s episode :15 Synovium 101 :22 Overview of the synovium and synovial fluid 2:06 How they figured it out? Dr. Marian Ropes 5:37 Investigating synovial fluid 7:46 Cows experiment and where synovial fluid comes from 11:25 Clinical review of synovial fluid 14:57 What’s inside the fluid? 18:54 What makes up the fluid? 20:51 How do things get out of the synovium? 23:19 How are things absorbed into the synovium? 27:21 How well do steroids get picked up systemically? 29:39 Summary 32:30 Thank you 34:59 Disclosures: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter References:
/episode/index/show/rheuminations/id/24164778
info_outline
SAPHO Part 2: An Abundance of Acronyms (AAOA)
07/26/2022
SAPHO Part 2: An Abundance of Acronyms (AAOA)
What does the PAPA spectrum disorder teach us about SAPHO? Is SAPHO an autoinflammatory condition or part of the SpA spectrum? Why have antibiotics been used to treat this condition? Find out in this episode! Brought to you by Tremfya. Intro :01 Welcome to another exciting episode of Rheuminations :11 About today’s episode :17 A summary of SAPHO Part 1 :24 What to expect in this episode 1:28 Earlier long-term data 2:27 A more recent paper from Italy 6:47 Therapeutics in detail 12:17 Summary so far 21:39 IL-1 inhibition in SAPHO 22:32 Monogenic pediatric conditions 33:58 Why can’t we check the genes in SAPHO? 40:00 Episode summary 41:55 We went through a lot in this paper 45:29 Thanks for listening 43:53 Disclosure: Brown reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Brown at . Follow us on Twitter and be sure to check out – your destination for rheumatology education and quizzes! References:
/episode/index/show/rheuminations/id/23868714